Transthyretin amyloid cardiomyopathy in France: A cross-sectional multi-centre study (333 patients) - Physiologie et physiopathologie endocriniennes - UMR-S 1185
Article Dans Une Revue Rare Année : 2024

Transthyretin amyloid cardiomyopathy in France: A cross-sectional multi-centre study (333 patients)

1 CHU Henri Mondor [Créteil]
2 IMRB - Institut Mondor de Recherche Biomédicale
3 Centre Hospitalier Universitaire [Rennes]
4 LTSI - Laboratoire Traitement du Signal et de l'Image
5 Service Cardiologie [CHU Toulouse]
6 CHU Dijon - Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand
7 Institut du Thorax [Nantes]
8 Centre Hospitalier Universitaire de Martinique [Fort-de-France, Martinique]
9 TransVIHMI - Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes
10 UM - Université de Montpellier
11 PhyMedExp - Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046]
12 AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
13 HEGP - Hôpital Européen Georges Pompidou [APHP]
14 University Hospital of Montpellier
15 AP-HP - Hôpital Bichat - Claude Bernard [Paris]
16 Pfizer
17 PHYSENDO - Physiologie et physiopathologie endocriniennes
18 Service de neurologie [Le Kremlin Bicêtre]
19 DHNS - Maladies et hormones du système nerveux
20 TIMONE - Hôpital de la Timone [CHU - APHM]
21 Département Neurologie [CHU Toulouse]
22 CHU Montpellier
23 CHUGA - Centre Hospitalier Universitaire [CHU Grenoble]
24 NNerf - Centre de référence national neuropathies périphériques rares [CHU Limoges]
25 Centre de reference des maladies neuromusculaires Nantes-Angers, CHU d'Angers et Nantes
26 Centre Medicina, Lyon
27 CHU Bordeaux
28 Centre de référence des maladies rares neuromusculaires
29 ICAN - Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases
30 CHU Amiens-Picardie
31 MP3CV - Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517
Olivier Lairez
Jean-Noël Trochu
Jérôme Adda
  • Fonction : Auteur
  • PersonId : 1101926
Agathe Coste
  • Fonction : Auteur
  • PersonId : 1130138
Mathilde Bartoli
  • Fonction : Auteur
Jérémie Rudant
  • Fonction : Auteur
  • PersonId : 838765
Lara Salvi
  • Fonction : Auteur
Shahram Attarian
Pascal Cintas
Raul Juntas Morales
Philippe Petiot
  • Fonction : Auteur
  • PersonId : 903741
Guilhem Solé
Silvia Oghina

Résumé

AimsWe designed a two-part epidemiological study, an observatory for amyloid transthyretin amyloidosis (OBSAMYL). The first objective was to identify and count the number of patients diagnosed with ATTR amyloidosis in participating French centres. The second was to evaluate the use and safety profile of tafamidis meglumine in real-world settings.MethodsThis was a non-interventional descriptive retrospective multi-centre national study. A census was conducted to estimate the number of patients diagnosed with ATTR amyloidosis who were still alive at the time of the study (defined as 1 June 2017). Patients with ATTR amyloidosis were contacted by French centres from the French Rare Diseases network program. Patients aged ≥18 years with hereditary transthyretin-mediated amyloidosis (ATTRv) or wild-type transthyretin amyloidosis (ATTRwt) or a pathogenic transthyretin (TTR) mutation were eligible.ResultsOf the 38 centres (13 cardiology and 25 neurology) invited to participate, 22 (60.5%) (10 cardiology, 12 neurology) participated. There were 333 patients in cardiology census population. Before diagnosis one-fourth of the patients had cardiac decompensation, and one-fifth had a pacemaker. The 177 ATTRwt-CM patients were older (80.1 ± 7.0 years versus 64.2 ± 14.3 years; P < 0.001), had a higher incidence of hypertension (51.4% versus 35.3%; P = 0.003), and a higher incidence of arrhythmia (45.8% versus 28.3%; P = 0.001) than 156 ATTRv patients. There were no differences in disease severity according to New York Heart Association classification. The ATTRv-mixed + CM group had more neurological symptoms (paraesthesia or dysesthesia, neuropathic pain, digestive disorders, and orthostatic hypotension) than the ATTRwt-CM group (P < 0.001). Biopsies were performed on nearly 90% of patients with most of them being positive. The most common biopsy sites were salivary glands (137 biopsies) and cardiac tissues (77 biopsies). Tafamidis meglumine was administered to 174 cardiology patients, including 96 with ATTRv-mixed, 61 with ATTRwt-CM, and 17 with ATTRv-CM. Tafamidis meglumine was generally well tolerated. 18 adverse events, including 12 severe adverse events were reported in 174 patients as safety-related incidents. Tafamidis meglumine was likely responsible for five adverse events, one of which was severe.ConclusionThis study of real-world clinical ATTR amyloidosis cases in France further elucidated the characteristics of and diagnostic approach to a cardiology patient population census of 333 patients. As of June 1, 2017, 177 ATTRwt-CM, 117 ATTRv-mixed, and 39 ATTRv-CM patients were alive. Our experience with tafamidis meglumine in the cardiology population confirmed its good tolerance.
Fichier principal
Vignette du fichier
1-s2.0-S2950008724000048-main.pdf (571.11 Ko) Télécharger le fichier
Origine Publication financée par une institution

Dates et versions

hal-04477521 , version 1 (24-05-2024)

Licence

Identifiants

Citer

Thibaud Damy, Erwan Donal, Olivier Lairez, Jean‐christophe Eicher, Mounira Karoubi, et al.. Transthyretin amyloid cardiomyopathy in France: A cross-sectional multi-centre study (333 patients). Rare, 2024, Rare, 2, pp.100021. ⟨10.1016/j.rare.2024.100021⟩. ⟨hal-04477521⟩
97 Consultations
41 Téléchargements

Altmetric

Partager

More